Research from Redeye, Redeye AB

Redeye

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye terminates its coverage of Polygiene and will cease providing research following quarterly reports or other business events for the company.</li><li>Redeye’s fair value range will be inactivated.</li></ul>

Redeye terminates its coverage of Polygiene and will cease providing research following quarterly reports or other business events for the company.Redeye’s fair value range will be inactivated.

<ul><li>As of today, Redeye places its coverage of Polygiene Group under review until further notice.</li><li>In the meantime, we will not comment on the development in the company and deactivate our valuation range.</li></ul>

As of today, Redeye places its coverage of Polygiene Group under review until further notice.In the meantime, we will not comment on the development in the company and deactivate our valuation range.

<ul><li>Redeye returns with an update following a softer-than-expected Q4 report.</li><li>We expect the challenging market conditions to remain for some time, thereby lowering our near-term forecast and valuation.</li><li>Still, we remain positive to the share, which has steeply declined over the last year, offering an opportunity for the long-term oriented.</li></ul>

Redeye returns with an update following a softer-than-expected Q4 report.We expect the challenging market conditions to remain for some time, thereby lowering our near-term forecast and valuation.Still, we remain positive to the share, which has steeply declined over the last year, offering an opportunity for the long-term oriented.

Polygiene Group (Q4 Review): Soft Finish to 2025, Long-Term Opportunity Intact

<ul><li>Redeye considers Polygiene’s Q4'25 figures to be soft, missing our expectations by 18% on top-line, primarily driven by lower Polygiene sales.</li><li>Subsequently, EBITDA missed our expectations, driven by the lower sales and one-time CEO shift costs impacting the quarter.</li><li>We expect to make downward estimate adjustments for 2026 while remaining positive to the long-term outlook.</li></ul>

Redeye considers Polygiene’s Q4'25 figures to be soft, missing our expectations by 18% on top-line, primarily driven by lower Polygiene sales.Subsequently, EBITDA missed our expectations, driven by the lower sales and one-time CEO shift costs impacting the quarter.We expect to make downward estimate adjustments for 2026 while remaining positive to the long-term outlook.

Polygiene Group (Q4 Initial take): Softer-than-Expected

<ul><li>Redeye comments on Polygiene's CEO shift that was announced today.</li></ul>

Redeye comments on Polygiene's CEO shift that was announced today.

Sweden

Polygiene Group AB develops, manufactures, and sells antimicrobial and odor control solutions for textiles and other surfaces. The company provides a wide range of technologies and treatments for products, serving partners across various categories, such as sports and outdoor, fashion and lifestyle, workwear, hospitality, home, and healthcare. It operates globally and offers its products under the Polygiene brand.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Polygiene Group (POLYG SS)

Polygiene: Redeye ceases coverage

Redeye terminates its coverage of Polygiene and will cease providing research following quarterly reports or other business events for the...

Redeye

Polygiene Group: Placed Under Review

As of today, Redeye places its coverage of Polygiene Group under review until further notice. In the meantime, we will not comment on the...

Redeye

Polygiene Group (Q4 Review): Soft Finish to 2025, Long-Term Opportunity Intact

Redeye returns with an update following a softer-than-expected Q4 report. We expect the challenging market conditions to remain for some time,...

Redeye

Polygiene Group (Q4 Initial take): Softer-than-Expected

Redeye considers Polygiene’s Q4'25 figures to be soft, missing our expectations by 18% on top-line, primarily driven by lower Polygiene...

Redeye

Polygiene Group: CEO Shift Announced

Redeye comments on Polygiene's CEO shift that was announced today.

Redeye

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)